- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.08. | Sight Sciences Announces FDA Label Expansion For TearCare Dry Eye Therapy | 1 | RTTNews | ||
| 19.08. | Sight Sciences, Inc.: TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease | 364 | GlobeNewswire (Europe) | MENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies... ► Artikel lesen | |
| 10.08. | Sight Sciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.08. | Sight Sciences outlines 2026 revenue of $88M-$92M while lowering adjusted operating expense outlook to $92M-$94M | 2 | Seeking Alpha | ||
| 06.08. | Sight Sciences GAAP EPS of -$0.08 beats by $0.06, revenue of $23.4M beats by $1.71M | 1 | Seeking Alpha | ||
| 05.08. | Earnings Call: Sight Sciences hebt Ausblick für 2026 an, Aktie fällt trotz Q2-Wachstum | - | Investing.com Deutsch | ||
| 05.08. | Sight Sciences: Aetna erweitert Kostenerstattung für Glaukom-Systeme | 7 | Investing.com Deutsch | ||
| 05.08. | Sight Sciences wins FDA clearance for Omni Surgical System | 2 | MassDevice | ||
| SIGHT SCIENCES Aktie jetzt für 0€ handeln | |||||
| 05.08. | FDA clears Sight Sciences' OMNI Ultra glaucoma device | 1 | Investing.com | ||
| 04.08. | Sight Sciences, Inc.: Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System | 127 | GlobeNewswire (Europe) | MENLO PARK, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies... ► Artikel lesen | |
| 22.07. | Sight Sciences, Inc.: Sight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026 | 1 | GlobeNewswire (USA) | ||
| 05.06. | Sight Sciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.05. | Sight Sciences signals $83M-$89M 2026 revenue outlook while targeting $6M-$8M dry eye sales | 1 | Seeking Alpha | ||
| 06.05. | Sight Sciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 23.04. | Sight Sciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.04. | Sight Sciences, Inc.: Sight Sciences Announces the Release of its Sustainability Report | 3 | GlobeNewswire (USA) | ||
| 21.04. | Sight Sciences, Inc.: Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026 | 2 | GlobeNewswire (USA) | ||
| 01.04. | Sight Sciences, Inc.: Sight Sciences' Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 30.03. | Sight Sciences secures $34M patent infringement win against Alcon | 3 | MassDevice | ||
| 30.03. | Sight Sciences wins $34M in Alcon patent case, ongoing royalty | 5 | Investing.com |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 5,672 | +1,18 % | BetterHelp Has the Demand: Can Teladoc Build the Capacity? | ||
| SERNOVA BIOTHERAPEUTICS | 0,065 | -7,12 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy | TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova" or the "Company") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals: Historischer Wendepunkt - darum fliegt die Aktie! | Volltreffer: Bereits im Frühjahr hatte ich die positive Entwicklung bei Sonoma Pharmaceuticals antizipiert und die Nano-Cap-Aktie als hochinteressante Turnaround-Spekulation vorgestellt. Damals hatte... ► Artikel lesen | |
| TANDEM DIABETES | 18,200 | -1,62 % | Tandem Diabetes Care, Inc.: Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets | Compatibility now available in five countries, with additional markets expected throughout 2026.Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company... ► Artikel lesen | |
| VERU | 2,630 | +0,19 % | Veru Inc.: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients - -- Phase 2b PLATEAU clinical trial interim analysis and... ► Artikel lesen | |
| SENSEONICS | 8,000 | -0,62 % | Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results | Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 1,080 | +1,89 % | Tempest Therapeutics, Inc. - 8-K, Current Report | ||
| VIRIDIAN THERAPEUTICS | 20,000 | 0,00 % | Aktien New York Ausblick: Nasdaq erholt - Comcast-Aufspaltung beflügelt Branche | NEW YORK (dpa-AFX) - Die Anleger dürften den jüngsten Kursrückschlag an der New Yorker Tech-Börse Nasdaq direkt zum Wiedereinstieg nutzen. Im Fokus stehen am Montag die jüngste Entspannung im davor... ► Artikel lesen | |
| SINTX TECHNOLOGIES | 1,490 | -0,67 % | SINTX Technologies, Inc.: SINTX Technologies Regains Compliance with Nasdaq Stockholders' Equity Requirement | SALT LAKE CITY, Utah, Aug. 13, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX" or the "Company"), a company focused on advanced silicon nitride materials and medical technologies... ► Artikel lesen | |
| VYOME | 2,205 | +2,08 % | Vyome Holdings, Inc - 8-K, Current Report | ||
| VIVANI MEDICAL | 1,110 | -0,89 % | Vivani Medical, Inc.: Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management | Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants. SLIM-1 trial is a Phase 1, randomized, controlled clinical trial design... ► Artikel lesen | |
| STEREOTAXIS | 1,262 | +1,12 % | Citizens lowers Stereotaxis stock price target to $3 on guidance cut | ||
| VIEMED HEALTHCARE | 7,400 | -3,90 % | Viemed Healthcare, Inc.: Viemed Healthcare Announces Second Quarter 2026 Financial Results | LAFAYETTE, LA / ACCESS Newswire / August 3, 2026 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic... ► Artikel lesen | |
| VIVOS THERAPEUTICS | 0,225 | 0,00 % | Vivos Therapeutics, Inc: Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center | ||
| TENON MEDICAL | 4,960 | -0,80 % | Tenon Medical, Inc.: Tenon Medical Announces Pricing of $3M Private Placement Offering | LOS GATOS, CA / ACCESS Newswire / August 28, 2026 / Tenon Medical, Inc. (NASDAQ:TNON), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today... ► Artikel lesen |
Das Unternehmen SIGHT SCIENCES INC kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 8,540 Euro und damit -0,12 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SIGHT SCIENCES INC finden Sie auf Wallstreet Online.